A carregar...
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas
Copanlisib, an intravenously administered agent with inhibitory activity that predominantly targets the alpha and delta isoforms of phosphoinositol 3-kinase, was granted accelerated approval by the United States Food and Drug Administration on the basis of its activity in the third-line treatment of...
Na minha lista:
| Publicado no: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6642803/ https://ncbi.nlm.nih.gov/pubmed/30584024 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2018.11.021 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|